Stonehage Fleming Financial Services Holdings Ltd Sells 77,640 Shares of Edwards Lifesciences Co. (NYSE:EW)

Stonehage Fleming Financial Services Holdings Ltd lowered its holdings in Edwards Lifesciences Co. (NYSE:EW) by 3.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,202,161 shares of the medical research company’s stock after selling 77,640 shares during the period. Edwards Lifesciences comprises about 4.6% of Stonehage Fleming Financial Services Holdings Ltd’s portfolio, making the stock its 11th largest holding. Stonehage Fleming Financial Services Holdings Ltd owned 0.37% of Edwards Lifesciences worth $163,026,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its position in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after purchasing an additional 3,506,886 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in Edwards Lifesciences by 239.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after purchasing an additional 2,606,950 shares during the last quarter. Seilern Investment Management Ltd bought a new position in Edwards Lifesciences during the fourth quarter worth about $109,490,000. Finally, Nordea Investment Management AB increased its position in Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after buying an additional 1,043,484 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 0.1 %

EW stock opened at $68.98 on Monday. The firm has a 50-day moving average price of $72.33 and a 200-day moving average price of $70.52. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a market capitalization of $40.68 billion, a P/E ratio of 9.95, a price-to-earnings-growth ratio of 3.54 and a beta of 1.11. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the prior year, the business posted $0.59 earnings per share. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Piper Sandler decreased their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Truist Financial reissued a “hold” rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Barclays lifted their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $82.00 to $90.00 in a research report on Monday, December 16th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $78.48.

Insider Activity

In related news, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,000 shares of company stock valued at $2,195,180 over the last three months. Corporate insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.